Immunosuppressive cells and tumour microenvironment: Focus on mesenchymal stem cells and myeloid derived suppressor cells

Histology and Histopathology

Volumn 26, Issue 7, 2011, Pages 941-951

  Bianchi, Giovanna ^a   Borgonovo, Giacomo ^b   Pistoia, Vito ^a   Raffaghello, Lizzia ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Immunosuppression; Mesenchymal stem cells; Myeloid derived suppressor cells; Tumour microenvironment

Indexed keywords

CYSTEINE; REACTIVE OXYGEN METABOLITE;

ANIMAL; BIOLOGICAL MODEL; BONE MARROW CELL; CANCER STEM CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; MESENCHYMAL STEM CELL; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; VASCULARIZATION;

ANIMALS; CYSTEINE; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MESENCHYMAL STEM CELLS; MODELS, IMMUNOLOGICAL; MYELOID CELLS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 79960672057     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Aggarwal S. and Pittenger M.F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 105, 1815-1822.
2. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., Carbone D.P. and Gabrilovich D.I. (2001). Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166, 678-689.
3. Annabi B., Naud E., Lee Y.T., Eliopoulos N. and Galipeau J. (2004). Vascular progenitors derived from murine bone marrow stromal cells are regulated by fibroblast growth factor and are avidly recruited by vascularizing tumours. J. Cell Biochem. 91, 1146-1158.
4. Bergfeld S.A. and DeClerck Y.A. (2010). Bone marrow-derived mesenchymal stem cells and the tumour microenvironment. Cancer Metastasis Rev. 29, 249-261.
5. Bexell D., Gunnarsson S., Tormin A., Darabi A., Gisselsson D., Roybon L., Scheding S. and Bengzon J. (2009). Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol. Ther. 17, 183-190.
6. Bingisser R.M., Tilbrook P.A., Holt P.G. and Kees U.R. (1998). Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J. Immunol. 160, 5729-5734.
7. Bissell M.J. and Radisky D. (2001). Putting tumours in context. Nat. Rev. Cancer. 1, 46-54.
8. Brandau S., Trellakis S., Bruderek K., Schmaltz D., Steller G., Elian M., Suttmann H., Schenck M., Welling J., Zabel P. and Lang S. (2010). Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J. Leukoc. Biol. 89, 311-317.
9. Brimnes M.K., Vangsted A.J., Knudsen L.M., Gimsing P., Gang A.O., Johnsen H.E. and Svane I.M. (2010). Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR/low myeloidderived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J. Immunol. 72, 540-547.
10. Brocke-Heidrich K., Kretzschmar A.K., Pfeifer G., Henze C., Löffler D., Koczan D., Thiesen H.J., Burger R., Gramatzki M. and Horn F. (2004). Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood 103, 242-251.
11. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N.P. and Zanovello P. (2000). Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 96, 3838-3846.
12. Bronte V. and Zanovello P. (2005). Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5, 641-654.
13. Burger J.A. and Kipps T.J. (2002). Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells. Leuk. Lymphoma 43, 461-466.
14. Cavarretta I.T., Altanerova V., Matuskova M., Kucerova L., Culig Z. and Altaner C. (2010). Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumour growth. Mol. Ther. 18, 223-231.
15. Condamine T. and Gabrilovich D.I. (2010). Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32, 19-25.
16. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., Risso M., Gualandi F., Mancardi G.L., Pistoia V. and Uccelli A. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood 107, 367-372.
17. Corzo C.A., Condamine T., Lu L., Cotter M.J., Youn J.I., Cheng P., Cho H.I., Celis E., Quiceno D.G., Padhya T., McCaffrey T.V., McCaffrey J.C. and Gabrilovich D.I. (2010). HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumour microenvironment. J. Exp. Med. 207, 2439-2453.
18. da Silva Meirelles L., Chagastelles P.C. and Nardi N.B. (2006). Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci. 119, 2204-2213.
19. Dannenberg A.J. and Subbaramaiah K. (2003). Targeting cyclooxigenase-2 in human neoplasia: rationale and promise. Cancer Cell. 4, 431.
20. De Santo C., Serafini P., Marigo I., Dolcetti L., Bolla M., del Soldato P., Melani C., Guiducci C., Colombo M.P., Iezzi M., Musiani P., Zanovello P. and Bronte V. (2005). Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumour eradication by cancer vaccination. Proc. Natl. Acad. Sci. USA 102, 4185-4190.
21. di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S. and Gianni A.M. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838-3843.
22. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., Noel D. and Jorgensen C. (2003). Immunosuppressive effect of mesenchymal stem cells favours tumour growth in allogeneic animals. Blood 102, 3837-3844.
23. Djouad F., Bony C., Apparailly F., Louis-Plence P., Jorgensen C. and Noel D. (2006). Earlier onset of syngeneic tumours in the presence of mesenchymal stem cells. Transplantation 82, 1060-1066.
24. Efferth T., Fabry U. and Osieka R. (2002). Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells. Anticancer Res. 22, 231-234.
25. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., Castelli C., Mariani L., Parmiani G. and Rivoltini L. (2007). Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25, 2546-2553.
26. Friedenstein A.J., Chailakhyan R.K., Latsinik N.V., Panasyuk A.F. and Keiliss-Borok I.V. (1974). Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 17, 331-340.
27. Fukaya Y., Shimada H., Wang L.C., Zandi E. and DeClerck Y.A. (2008). Identification of galectin-3-binding protein as a factor secreted by tumour cells that stimulates interleukin-6 expression in the bone marrow stroma. J. Biol. Chem. 283, 18573-18581.
28. Gabrilovich D.I. and Nagaraj S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174.
29. Gabrilovich D.I., Velders M.P., Sotomayor E.M. and Kast W.M. (2001). Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 166, 5398-5406.
30. Galie M., Konstantinidou G., Peroni D., Scambi I., Marchini C., Lisi V., Krampera M., Magnani P., Merigo F., Montani M., Boschi F., Marzola P., Orru R., Farace P., Sbarbati A. and Amici A. (2008). Mesenchymal stem cells share molecular signature with mesenchymal tumour cells and favour early tumour growth in syngeneic mice. Oncogene 27, 2542-2551.
31. Galmiche M.C., Koteliansky V.E., Briere J., Herve P. and Charbord P. (1993). Stromal cells from human long-term marrow cultures are mesenchymal cells that differentiate following a vascular smooth muscle differentiation pathway. Blood 82, 66-76.
32. Hoechst B., Ormandy L.A., Ballmaier M., Lehner F., Kruger C., Manns M.P., Greten T.F. and Korangy F. (2008). A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135, 234-243.
33. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M. and Chen S.H. (2006). Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumour-bearing host. Cancer Res. 66, 1123-1131.
34. Hung S.C., Deng W.P., Yang W.K., Liu R.S., Lee C.C., Su T.C., Lin R.J., Yang D.M., Chang C.W., Chen W.H., Wei H.J. and Gelovani J.G. (2005). Mesenchymal stem cell targeting of microscopic tumours and tumour stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin. Cancer Res. 11, 7749-7756.
35. Iwamoto S., Mihara K., Downing J.R., Pui C.H. and Campana D. (2007). Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J. Clin. Invest. 117, 1049-1057.
36. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D. and Mao N. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105, 4120-4126.
37. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R. and Weinberg R.A. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-563.
38. Khakoo A.Y., Pati S., Anderson S.A., Reid W., Elshal M.F., Rovira, I.I, Nguyen A.T., Malide D., Combs C.A., Hall G., Zhang J., Raffeld M., Rogers T.B., Stetler-Stevenson W., Frank J.A., Reitz M. and Finkel T. (2006). Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med. 203, 1235-1247.
39. Kidd S., Spaeth E., Klopp A., Andreeff M., Hall B., and Marini F.C. (2008). The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy 10, 657-667.
40. Kidd S., Spaeth E., Dembinski J.L., Dietrich M., Watson K., Klopp A., Battula V.L., Weil M., Andreeff M. and Marini F.C. (2009). Direct evidence of mesenchymal stem cell tropism for tumour and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 27, 2614-2623.
41. Kidd S., Caldwell L., Dietrich M., Samudio I., Spaeth E.L., Watson K., Shi Y., Abbruzzese J., Konopleva M., Andreeff M. and Marini F.C. (2010). Mesenchymal stromal cells alone or expressing interferonbeta suppress pancreatic tumours in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 12, 615-625.
42. Kinnaird T., Stabile E., Burnett M.S., Lee C.W., Barr S., Fuchs S. and Epstein S.E. (2004). Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ. Res. 94, 678-685.
43. Koc O.N., Gerson S.L., Cooper B.W., Dyhouse S.M., Haynesworth S.E., Caplan A.I. and Lazarus H.M. (2000). Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and cultureexpanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J. Clin. Oncol. 18, 307-316.
44. Kusmartsev S., Cheng F., Yu B., Nefedova Y., Sotomayor E., Lush R. and Gabrilovich D.I. (2003). All-trans-retinoic acid eliminates immature myeloid cells from tumour-bearing mice and improves the effect of vaccination. Cancer Res. 63, 4441-4449.
45. Kusmartsev S., Eruslanov E., Kubler H., Tseng T., Sakai Y., Su Z., Kaliberov S., Heiser A., Rosser C., Dahm P., Siemann D. and Vieweg J. (2008). Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumour-induced immune suppression in renal cell carcinoma. J. Immunol. 181, 346-353.
46. Lathers D.M., Clark J.I., Achille N.J. and Young M.R. (2004). Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol. Immunother. 53, 422-430.
47. Lazarus H.M., Koc O.N., Devine S.M., Curtin P., Maziarz R.T., Holland H.K., Shpall E.J., McCarthy P., Atkinson K., Cooper B.W., Gerson S.L., Laughlin M.J., Loberiza F.R. Jr, Moseley A.B. and Bacigalupo A. (2005). Cotransplantation of HLA-identical sibling cultureexpanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transplant. 11, 389-398.
48. Liu C., Yu S., Kappes J., Wang J., Grizzle W.E., Zinn K.R. and Zhang H.G. (2007). Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumour-bearing host. Blood 109, 4336-4342.
49. Liu C.Y., Wang Y.M., Wang C.L., Feng P.H., Ko H.W., Liu Y.H., Wu Y.C., Chu Y., Chung F.T., Kuo C.H., Lee K.Y., Lin S.M., Lin H.C., Wang C.H., Yu C.T. and Kuo H.P. (2009). Population alterations of L: -arginase- and inducible nitric oxide synthase-expressed CD11b(+)/CD14 (-)/CD15 (+)/CD33 (+) myeloid-derived suppressor cells and CD8 (+) T lymphocytes in patients with advanced-stage non-small cell lung cancer. J. Cancer Res. Clin. Oncol., 136, 35-45.
50. Mandruzzato S., Solito S., Falisi E., Francescato S., Chiarion-Sileni V., Mocellin S., Zanon A., Rossi C.R., Nitti D., Bronte V. and Zanovello P. (2009). IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 182, 6562-6568.
51. Melani C., Sangaletti S., Barazzetta F.M., Werb Z. and Colombo M.P. (2007). Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumour-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumour stroma. Cancer Res. 67, 11438-11446.
52. Michigami T., Shimizu N., Williams P.J., Niewolna M., Dallas S.L., Mundy G.R. and Yoneda T. (2000). Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclaststimulating activity. Blood 96, 1953-1960.
53. Mirza N., Fishman M., Fricke I., Dunn M., Neuger A.M., Frost T.J., Lush R.M., Antonia S. and Gabrilovich D.I. (2006). All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66, 9299-9307.
54. Molloy A.P., Martin F.T., Dwyer R.M., Griffin T.P., Murphy M., Barry F.P., O'Brien T. and Kerin M.J. (2009). Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int. J. Cancer 124, 326-332.
55. Morandi F., Raffaghello L., Bianchi G., Meloni F., Salis A., Millo E., Ferrone S., Barnaba V. and Pistoia V. (2008). Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumour-associated antigens. Stem Cells 26, 1275-1287.
56. Movahedi K., Guilliams M., Van den Bossche J., van den Bergh R., Gysemans C., Beschin A., De Baetselier P. and van Ginderachter J.A. (2008). Identification of discrete tumour-induced myeloid- derived suppressor cell subpopulations with distinct T cellsuppressive activity. Blood. 111, 4233-4244.
57. Nagaraj S. and Gabrilovich D.I. (2010). Myeloid-derived suppressor cells in human cancer. Cancer J. 16, 348-353.
58. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber D.L., Schneck J. and Gabrilovich D.I. (2007). Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13, 828-835.
59. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., Chen J., Hentschel S., Vecil G., Dembinski J., Andreeff M. and Lang F.F. (2005). Human bone marrow-derived mesenchymal stem cellsin the treatment of gliomas. Cancer Res. 65, 3307-3318.
60. Nausch N., Galani I.E., Schlecker E. and Cerwenka A. (2008). Mononuclear myeloid-derived suppressor cells express RAE-1 and activate natural killer cells. Blood 112, 4080-4089.
61. Nauta A.J., Kruisselbrink A.B., Lurvink E., Willemze R. and Fibbe W.E. (2006). Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J. Immunol. 177, 2080-2087.
62. Nauta A.J. and Fibbe W.E. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood. 110, 3499-3506.
63. Ning H., Yang F., Jiang M., Hu L., Feng K., Zhang J., Yu Z., Li B., Xu C., Li Y., Wang J., Hu J., Lou X. and Chen H. (2008). The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22, 593-599.
64. Ochoa A.C., Zea A.H., Hernandez C. and Rodriguez P.C. (2007). Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 13, 721s-726s.
65. Ostrand-Rosenberg S. (2010). Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 59, 1593-1600.
66. Patel S.A., Meyer J.R., Greco S.J., Corcoran K.E., Bryan M. and Rameshwar P. (2010). Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J. Immunol. 184, 5885-5894.
67. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S. and Bronte V. (2010). Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22, 238-244.
68. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S. and Marshak D.R. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147.
69. Prigione I., Benvenuto F., Bocca P., Battistini L., Uccelli A. and Pistoia V. (2009). Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells 27, 693-702.
70. Raffaghello L., Bianchi G., Bertolotto M., Montecucco F., Busca A., allegri F., Ottonello L. and Pistoia V. (2008). Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 26, 151-162.
71. Ramasamy R., Lam E.W., Soeiro I., Tisato V., Bonnet D. and Dazzi F. (2007). Mesenchymal stem cells inhibit proliferation and apoptosis of tumour cells: impact on in vivo tumour growth. Leukemia. 21, 304-310.
72. Rasmusson I., Ringden O., Sundberg B. and le Blanc K. (2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation. 76, 1208-1213.
73. Rivoltini L., Carrabba M., Huber V., Castelli C., Novellino L., Dalerba P., Mortarini R., Arancia G., Anichini A., Fais S. and Parmiani G. (2002). Immunity to cancer: attack and escape in T lymphocyte-tumour cell interaction. Immunol. Rev. 188, 97-113.
74. Rodriguez P.C., Zea A.H., Culotta K.S., Zabaleta J., Ochoa J.B. and Ochoa A.C. (2002). Regulation of T cell receptor CD3zeta chain expression by L-arginine. J. Biol. Chem. 277, 21123-21129.
75. Rodriguez P.C., Quiceno D.G., Zabaleta J., Ortiz B., Zea A.H., Piazuelo M.B., Delgado A., Correa P., Brayer J., Sotomayor E.M., Antonia S., Ochoa J.B. and Ochoa A.C. (2004). Arginase I production in the tumour microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64, 5839-5849.
76. Rodriguez P.C., Hernandez C.P., Quiceno D., Dubinett S.M., Zabaleta J., Ochoa J.B., Gilbert J. and Ochoa A.C. (2005). Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J. Exp. Med. 202, 931-939.
77. Rodriguez P.C., Quiceno D.G. and Ochoa A.C. (2007). L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109, 1568-1573.
78. Rodriguez P.C., Ernstoff M.S., Hernandez C., Atkins M., Zabaleta J., Sierra R. and Ochoa A.C. (2009). Arginase I-producing myeloidderived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69, 1553-1560.
79. Roorda B.D., ter Elst A., Kamps W.A. and de Bont E.S. (2009). Bone marrow-derived cells and tumor growth: contribution of bone marrow-derived cells to tumour micro-environments with special focus on mesenchymal stem cells. Crit. Rev. Oncol. Hematol. 69, 187-198.
80. Sakakura Y., Sato H., Shiiya A., Tamba M., Sagara J., Matsuda M., Okamura N., Makino N. and Bannai S. (2007). Expression and function of cystine/glutamate transporter in neutrophils. J. Leukoc. Biol. 81, 974-982.
81. Sasportas L.S., Kasmieh R., Wakimoto H., Hingtgen S., van de Water J.A., Mohapatra G., Figueiredo J.L., Martuza R.L., Weissleder R. and Shah K. (2009). Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc. Natl. Acad. Sci. USA 106, 4822-4827.
82. Secchiero P., Zorzet S., Tripodo C., Corallini F., Melloni E., Caruso L., Bosco R., Ingrao S., Zavan B. and Zauli G. (2010). Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS One 5, e11140.
83. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., Borg C., Saas P., Tiberghien P., Rouas-Freiss N., Carosella E.D. and Deschaseaux F. (2008). Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress Tlymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells. 26, 212-222.
84. Serafini P., Mgebroff S., Noonan K. and Borrello I. (2008). Myeloidderived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 68, 5439-5449.
85. Sinha P., Clements V.K. and Ostrand-Rosenberg S. (2005). Interleukin- 13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res. 65, 11743-11751.
86. Sinha P., Clements V.K., Bunt S.K., Albelda S.M. and Ostrand-Rosenberg S. (2007). Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumour immunity toward a type 2 response. J. Immunol. 179, 977-983.
87. Sohara Y., Shimada H., Minkin C., Erdreich-Epstein A., Nolta J.A. and DeClerck Y.A. (2005). Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res. 65, 1129-1135.
88. Spaeth E., Klopp A., Dembinski J., Andreeff M. and Marini F. (2008). Inflammation and tumour microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 15, 730-738.
89. Spaeth E.L., Dembinski J.L., Sasser A.K., Watson K., Klopp A., Hall B., Andreeff M. and Marini F. (2009). Mesenchymal stem cell transition to tumour-associated fibroblasts contributes to fibrovascular network expansion and tumour progression. PLoS One 4, e4992.
90. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C. and Moretta L. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107, 1484-1490.
91. Spaggiari G.M., Capobianco A., Abdelrazik H., Becchetti F., Mingari M.C. and Moretta L. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111, 1327-1333.
92. Srivastava M.K., Sinha P., Clements V.K., Rodriguez P. and Ostrand- Rosenberg S. (2010). Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70, 68-77
93. Studeny M., Marini F.C., Champlin R.E., Zompetta C., Fidler I.J. and Andreeff M. (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 62, 3603-3608.
94. Studeny M., Marini F.C., Dembinski J.L., Zompetta C., Cabreira-Hansen M., Bekele B.N., Champlin R.E. and Andreeff M. (2004). Mesenchymal stem cells: potential precursors for tumour stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst. 96, 1593-1603.
95. Suzuki E., Kapoor V., Jassar A.S., Kaiser L.R. and Albelda S.M. (2005). Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11, 6713-6721.
96. Taketo M.M. (1998). Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl. Cancer Inst. 90, 1529-1536.
97. Talmadge J.E. (2007). Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin. Cancer Res. 13, 5243-5248.
98. Talmadge JE, Hood KC, Zobel LC, Shafer LR, Coles M and Toth B. (2007bis). Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int. Immunopharmacol. 7, 140-151.
99. Uccelli A., Moretta L. and Pistoia V. (2006). Immunoregulatory function of mesenchymal stem cells. Eur. J. Immunol. 36, 2566-2573.
100. Uccelli A., Moretta L. and Pistoia V. (2008). Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8, 726-736.
101. Urashima M., Chen B.P., Chen S., Pinkus G.S., Bronson R.T., Dedera D.A., Hoshi Y., Teoh G., Ogata A., Treon S.P., Chauhan D. and Anderson K.C. (1997). The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 90, 754-765.
102. Whiteside T.L. (2008). The tumour microenvironment and its role in promoting tumour growth. Oncogene. 27, 5904-5912
103. Whiteside T.L. (2006). Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 16, 3-15.
104. Xu W.T., Bian Z.Y., Fan Q.M., Li G. and Tang T.T. (2009). Humanmesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett. 281, 32-41.
105. Yang R., Cai Z., Zhang Y., Yutzy W.H.T., Roby K.F. and Roden R.B. (2006). CD80 in immune suppression by mouse ovarian carcinomaassociated Gr-1+CD11b+ myeloid cells. Cancer Res. 66, 6807-6815.
106. Youn J.I., Nagaraj S., Collazo M. and Gabrilovich D.I. (2008). Subsets of myeloid-derived suppressor cells in tumour-bearing mice. J. Immunol. 181, 5791-5802.